表紙
市場調查報告書
商品編碼
909459

病毒載體製造的全球市場

Viral Vector Manufacturing

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 402 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球病毒載體製造市場相關調查分析,提供市場概要,主要企業,市場趨勢·促進因素,全球市場預測,各地區市場分析,競爭情形相關的系統性資訊。

第1章 調查手法

第2章 摘要整理

  • 市場概要
    • 全球競爭企業的市場佔有率
  • 主要企業
  • 市場趨勢·促進因素
  • 全球市場預測

第3章 市場分析

  • 各地區市場分析
    • 美國
    • 加拿大
    • 日本
    • 中國
    • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 其他的歐洲
    • 亞太地區
    • 其他全球地區

第4章 競爭

  • CELL AND GENE THERAPY CATAPULT
  • COBRA BIOLOGICS
  • FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A.
  • LONZA GROUP AG
  • MERCK KGAA
  • OXFORD BIOMEDICA PLC
  • SPARK THERAPEUTICS
  • UNIQURE NV

第5章 相關調查

目錄
Product Code: MCP15508

What`s New for 2022?

» Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

» Online interactive peer-to-peer collaborative bespoke updates

» Access to our digital archives and MarketGlass Research Platform

» Complimentary updates for one year

Global Viral Vector Manufacturing Market to Reach $1.2 Billion by 2026

Viral vectors are tools that find common usage in molecular biology related research, for the main purpose of delivering genetic materials to cells. The process of delivery is performed in vivo or inside the living organism and also in vitro or within cell culture. Viruses were able to evolve distinct molecular mechanisms which allow effective transmission of their genomes in the cells that they infect. The process of genetic material or genes delivery using a vector is called transduction. The cells that are infected are referred to as the transduced. Viral vectors were used by molecular biologists as early as in the 70s. SV40, a modified virus with DNA from bacteriophage ?, was used for infecting cells in monkey kidney. Viral vectors are currently being used for vaccines development and gene therapy in addition to their use in molecular biology. Though viral vectors are generally customized to suit specific applications, they have certain common properties in terms of safety, stability, toxicity, cell type specificity and identification. Usually, viral vectors are derived from viruses that are pathogenic. Modification is done to minimize risks while handling. Modification involves elimination of a viral genome part that is important for the replication of the virus. A modified virus requires helpers to produce new versions and therefore only effective for so long as to infect the cells. Another important property of viral vectors is that they are of low toxicity, having limited impact on cell physiology. Also, certain viruses are unstable genetically. They rearrange genomes rapidly which can be damaging to reproducibility and predictability of work done using viral vectors.

Amid the COVID-19 crisis, the global market for Viral Vector Manufacturing estimated at US$450.5 Million in the year 2020, is projected to reach a revised size of US$1.2 Billion by 2026, growing at a CAGR of 18.5% over the analysis period. Retroviral Vectors, one of the segments analyzed in the report, is projected to record a 18.5% CAGR and reach US$547.1 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Adenoviral Vectors segment is readjusted to a revised 18.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $327.6 Million in 2021, While China is Forecast to Reach $49 Million by 2026

The Viral Vector Manufacturing market in the U.S. is estimated at US$327.6 Million in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$49 Million by the year 2026 trailing a CAGR of 21.9% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 15.8% and 16% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.1% CAGR.

The increasing prevalence of various genetic disorders and target diseases such as infectious diseases, increased funding availability for development of gene therapy, research efforts in the field of viral vector based cell and gene therapies, and increasing efficacy of viral vectors in delivering gene therapy are fueling growth in the global viral vectors manufacturing market. The growing investments into biopharmaceutical production, rising healthcare spending, technology advancements and healthcare needs of aging population are fueling growth in the viral vectors market. Rise in number of clinical studies, and potential applications in novel drug delivery approaches are also fueling growth in the market. Several viral vector-based drugs have already been approved including Gendicine™, which is the foremost gene therapy drug based on oncolytic adenovirus vector; StrimvelisR, a lentivirus vector for severe combined immunodeficiency (SCID); GlyberaRR, a recombinant AAV for addressing lipoprotein lipase deficiency.

Adeno-Associated Viral Vectors Segment to Reach $287.8 Million by 2026

AAVs or adeno-associated viruses are those that infect primate species and humans commonly. Even though they do not cause major diseases and only result in a minor immune response, the viruses are able to infect non-dividing as well as dividing cells and incorporate virus genome into host cell. AAV also stays in the form of episomal mostly, performing stable and long expression - features which make the viruses attractive candidates for viral vectors` creation, to be used in gene therapy. In the global Adeno-associated Viral Vectors segment, USA, Canada, Japan, China and Europe will drive the 19.7% CAGR estimated for this segment. These regional markets accounted for a combined market size of US$89.5 Million in the year 2020. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$8.2 Million by the year 2026.

Select Competitors (Total 80 Featured) -

  • Batavia Biosciences B.V.
  • BioNTech IMFS GmbH
  • Cobra Biologics Ltd.
  • FinVector Oy
  • FUJIFILM Diosynth Biotechnologies
  • Genelux Corporation
  • Kaneka Eurogentec S.A.
  • Lonza Group AG
  • MaxCyte, Inc.
  • Merck KGaA
  • Novasep Inc.
  • Oxford BioMedica plc
  • Sirion-Biotech GmbH
  • Spark Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
  • Vector Biolabs
  • Vigene Biosciences, Inc.
  • Virovek, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of COVID-19 Pandemic and Looming Global Recession
    • With Viral Vector-based Vaccines Used for COVID-19 in Development, Viral Vector Manufacturing Market Poised to Benefit
    • An Introduction to Viral Vector Manufacturing
    • Applications of Viral Vectors
    • Types of Viral Vectors
    • Global Viral Vector Manufacturing Market: Prospects & Outlook
    • Competition
    • COVID-19 Pandemic Puts Pressure on Already Constrained Viral Vector Manufacturing Capacity
    • A Glance at Select Investments in Expanding Viral Vector Manufacturing Capacity
    • Recent Market Activity
    • Viral Vector Manufacturing - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Infectious Diseases, Genetic Disorders & Cancers Drives Market
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Life Expectancy at Age 60 and 80 Years: (2010-2015), (2020-2025) & (2045-2050)
    • Gene Therapy Emerges as a Major Therapeutic Approach for Inheritable and Acquired Diseases, Spurring Market Prospects
    • Gene Therapy Set to Witness Rapid Growth Post COVID-19
    • Viral Vectors Lead the Gene Therapy Market
    • Adeno-Associated Virus Vectors: A Leading Platform for Gene Therapy
    • Lentiviral Vectors Witness Increased Interest for Gene Therapy
    • Funding Support for Gene Therapy Development Presents Market Opportunities
    • Complexity in Viral Vector Production for Gene therapies
    • Amidst Rising Cancer Incidence, Focus on Viral Vector-based Gene Therapies to Boost Market
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
    • Number of New Cancer Cases and Deaths (in Million) by Region for 2018
    • Engineered and Natural Oncolytic Viral Vectors: A Key Development in Viral Vector-based Cancer Therapy
    • Growing Threat Posed by Infectious Diseases Drives Focus onto Vector Viral-based Therapies & Vaccines
    • Infectious Diseases Remain Major Cause of Death in Under Developed Regions: Breakdown of Leading Causes of Death in Sub-Saharan Africa (in %)
    • Infectious Diseases Related Mortality High Among Children Below 5 Years: Breakdown of Leading Causes of Death in Children Below 5 Years (in %)
    • Rising Significance of Viral Vectors in New Vaccine Development
    • Adenovirus-based Vaccines: Evolution Over the Years
    • Viral Vector Emerges as a Next-Gen Platform for COVID-19 Vaccines Development
    • Rush to Develop and Rollout COVID-19 Vaccines Boosts Prospects for Viral Vector Manufacturing
    • COVID-19 Vaccines Under Development
    • Vaccines in Pipeline by Technology
    • Vaccine Technologies in Pre-Clinical Studies
    • Replicating and Non-Replicating Viral Vector-Based Vaccines
    • Non-Replicating Viral vector Vaccine in Clinical Development: As on December 2nd, 2020
    • Replicating Viral vector Vaccine Candidate in Clinical Development: As on December 2nd, 2020
    • Adenoviral Vectors: Frontrunners of New Vaccine for COVID-19
    • Vaccines for COVID-19 Confronts Logistic Obstacles to Overcome
    • Market to Benefit from the Emergence of New Technologies to Manufacture Viral Vectors
    • New Trends for Optimizing Workflow Using Viral Vectors
    • Production Workflow & Viral Vectors
    • Closed-System-Adherent Culture of Cells: Recent Advances
    • Limitations in Viral Vector Manufacturing Impact Market
    • Innovations & Collaborations: Essential to Resolve Challenges Facing Large-Scale GMP Viral Vector Manufacturing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Viral Vector Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 3: World 11-Year Perspective for Viral Vector Manufacturing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2016, 2021 & 2027
    • TABLE 4: World Recent Past, Current & Future Analysis for Retroviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Retroviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 6: World 11-Year Perspective for Retroviral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
    • TABLE 7: World Recent Past, Current & Future Analysis for Adenoviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Adenoviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 9: World 11-Year Perspective for Adenoviral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
    • TABLE 10: World Recent Past, Current & Future Analysis for Adeno-associated Viral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Adeno-associated Viral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 12: World 11-Year Perspective for Adeno-associated Viral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 15: World 11-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
    • TABLE 16: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 18: World 11-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
    • TABLE 19: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 21: World 11-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
    • TABLE 22: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 24: World 11-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
    • TABLE 25: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 27: World 11-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
    • TABLE 28: World Recent Past, Current & Future Analysis for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 30: World 11-Year Perspective for Pharma & Biopharma Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
    • TABLE 31: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 33: World 11-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
    • TABLE 34: USA Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: USA Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 36: USA 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
    • TABLE 37: USA Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: USA Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 39: USA 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
    • TABLE 40: USA Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: USA Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 42: USA 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
  • CANADA
    • TABLE 43: Canada Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Canada Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 45: Canada 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Canada Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 48: Canada 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
    • TABLE 49: Canada Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Canada Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 51: Canada 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
  • JAPAN
    • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Japan Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 54: Japan 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
    • TABLE 55: Japan Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Japan Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 57: Japan 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
    • TABLE 58: Japan Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Japan Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 60: Japan 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
  • CHINA
    • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
    • TABLE 61: China Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: China Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 63: China 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
    • TABLE 64: China Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: China Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 66: China 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
    • TABLE 67: China Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: China Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 69: China 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
  • EUROPE
    • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 71: Europe Historic Review for Viral Vector Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 72: Europe 11-Year Perspective for Viral Vector Manufacturing by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2016, 2021 & 2027
    • TABLE 73: Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Europe Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 75: Europe 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
    • TABLE 76: Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Europe Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 78: Europe 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
    • TABLE 79: Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Europe Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 81: Europe 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
  • FRANCE
    • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
    • TABLE 82: France Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: France Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 84: France 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
    • TABLE 85: France Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: France Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 87: France 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
    • TABLE 88: France Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: France Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 90: France 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
  • GERMANY
    • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
    • TABLE 91: Germany Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Germany Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 93: Germany 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
    • TABLE 94: Germany Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Germany Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 96: Germany 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
    • TABLE 97: Germany Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Germany Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 99: Germany 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
  • ITALY
    • TABLE 100: Italy Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Italy Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 102: Italy 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
    • TABLE 103: Italy Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Italy Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 105: Italy 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
    • TABLE 106: Italy Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Italy Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 108: Italy 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
  • UNITED KINGDOM
    • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
    • TABLE 109: UK Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: UK Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 111: UK 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
    • TABLE 112: UK Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: UK Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 114: UK 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
    • TABLE 115: UK Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: UK Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 117: UK 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
  • REST OF EUROPE
    • TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Rest of Europe Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 120: Rest of Europe 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
    • TABLE 121: Rest of Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Rest of Europe Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 123: Rest of Europe 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
    • TABLE 124: Rest of Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Rest of Europe Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 126: Rest of Europe 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
  • ASIA-PACIFIC
    • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
    • TABLE 127: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Asia-Pacific Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 129: Asia-Pacific 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
    • TABLE 130: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Asia-Pacific Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 132: Asia-Pacific 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
    • TABLE 133: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Asia-Pacific Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 135: Asia-Pacific 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
  • REST OF WORLD
    • TABLE 136: Rest of World Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Rest of World Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 138: Rest of World 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
    • TABLE 139: Rest of World Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Rest of World Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 141: Rest of World 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
    • TABLE 142: Rest of World Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Rest of World Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 144: Rest of World 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027

IV. COMPETITION

  • Total Companies Profiled: 80